

# Cellulitis and erysipelas: antimicrobial prescribing - guideline consultation



**Consultation on draft guideline – deadline for comments 17.00 on 10/05/2019 email: [infections@nice.org.uk](mailto:infections@nice.org.uk)**

	<p>Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly.</p> <p>We would like to hear your views on the draft recommendations</p> <p>We would like to hear your views on these questions:</p> <ol style="list-style-type: none"><li>1. Which areas will have the biggest impact on practice and be challenging to implement? Please say for whom and why.</li><li>2. What would help users overcome any challenges? (For example, existing practical resources or national initiatives, or examples of good practice.)</li><li>3. For the <b>guideline</b>:<ul style="list-style-type: none"><li>○ Are there any recommendations that will be a significant change to practice or will be difficult to implement? If so, please give reasons why.</li><li>○ What are the key issues or learning points for professional groups?</li><li>○ With regard to section 1.2 (table 1 and 2), is 7 days an appropriate duration of antibiotic treatment, with a footnote to explain that a longer course of up to a further 7 days may be needed based on clinical assessment?</li></ul></li></ol> <p>See section 3.9 of <a href="#">Developing NICE guidance: how to get involved</a> for suggestions of general points to think about when commenting.</p>
<b>Organisation name – Stakeholder or respondent</b> (if you are responding as an individual rather than a registered stakeholder please leave blank):	Royal Pharmaceutical Society
<b>Disclosure</b> Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry.	
<b>Name of commentator person completing form:</b>	Heidi Wright

Please return to: [infections@nice.org.uk](mailto:infections@nice.org.uk)

# Cellulitis and erysipelas: antimicrobial prescribing - guideline consultation



Consultation on draft guideline – deadline for comments 17.00 on 10/05/2019 email: [infections@nice.org.uk](mailto:infections@nice.org.uk)

Type		[office use only]		
Comment number	Document (guideline, evidence review or the visual summary)	Page number Or 'general' for comments on the whole document	Line number Or 'general' for comments on the whole document	Comments
				<p>Insert each comment in a new row. Do not paste other tables into this table, because your comments could get lost – type directly into this table.</p>
1	Draft Guideline	General	General	Course length of 7 days with option for additional 7 days seems reasonable
2	Draft Guideline	General	General	There is no mention of OPAT which is an increasingly common approach to managing patients with cellulitis to reduce hospital stay
3	Draft guideline	4 and 5	table	<ul style="list-style-type: none"> <li>• Doxycycline/cotrimoxazole is not mentioned as an alternative and probably should be for penicillin allergic outpatient treatment or step down.</li> <li>• Clindamycin needs a warning around for those at risk of CDI.</li> <li>• Query use of Cefuroxime given the range of alternatives</li> <li>• Unsure why Gentamicin is included – only useful in someone very unwell and should be indicated that this is when used.</li> <li>• Add cautions around linezolid use in view of the many interactions/ contraindications and monitoring requirements due to toxicity</li> </ul>

Insert extra rows as needed

## Checklist for submitting comments

- Use this comment form and submit it as a Word document (not a PDF).
- Complete the disclosure about links with, or funding from, the tobacco industry.
- Include page and line number (not section number) of the text each comment is about.
- Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation.
- Do not paste other tables into this table – type directly into the table.
- Underline and highlight any confidential information or other material that you do not wish to be made public.
- Do not include medical information about yourself or another person from which you or the person could be identified.
- Spell out any abbreviations you use

Please return to: [infections@nice.org.uk](mailto:infections@nice.org.uk)

## Cellulitis and erysipelas: antimicrobial prescribing - guideline consultation

**NICE** National Institute for  
Health and Care Excellence

**Consultation on draft guideline – deadline for comments 17.00 on 10/05/2019 email:**  
[infections@nice.org.uk](mailto:infections@nice.org.uk)

- For copyright reasons, comment forms do not include attachments such as research articles, letters or leaflets (for copyright reasons). We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments, but it must be received by the deadline.

You can see any guidance that we have produced on topics related to this guideline by checking [NICE Pathways](#).

**Note:** We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.